The Economic Burden of Acute Myeloid Leukemia in Iran
Background: Cancer imposes a significant economic burden on the health system and society. Acute myeloid leukemia (AML) is the third deadliest leukemia and is one of the leading health problems worldwide. The present study aimed to estimate the economic burden of AML in Iran for 2020. Methods: I...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2022-11-01
|
| Series: | Iranian Journal of Public Health |
| Subjects: | |
| Online Access: | https://ijph.tums.ac.ir/index.php/ijph/article/view/24990 |
| _version_ | 1797963409264738304 |
|---|---|
| author | Vahid Alipour Soroush Rad Shahin Nargesi Fateme Mezginejad Reza Jahangiri Zeinab Dolatshahi Seyed Asadollah Mousavi Zahra Moshkani |
| author_facet | Vahid Alipour Soroush Rad Shahin Nargesi Fateme Mezginejad Reza Jahangiri Zeinab Dolatshahi Seyed Asadollah Mousavi Zahra Moshkani |
| author_sort | Vahid Alipour |
| collection | DOAJ |
| description |
Background: Cancer imposes a significant economic burden on the health system and society. Acute myeloid leukemia (AML) is the third deadliest leukemia and is one of the leading health problems worldwide. The present study aimed to estimate the economic burden of AML in Iran for 2020.
Methods: In this study, we estimated a prevalence-based on the cost-of-illness of the AML in Iran. A societal perspective was considered, in which the direct costs and productivity losses with the adoption of the human capital approach in the AML cases were estimated for 2020. Moreover, in the present study, several resources including national cancer registry reports, hospital records, occupational data, and interviews with experts were cited.
Results: Approximately 98% of patients with AML received induction therapy. The AML economic burden was $33,243,107.39. Indirect costs accounted for 60% (21,593,764.4$) of this amount, and direct medical costs and direct non-medical costs make up for 19% (6,359,380.88$) and 16% (5,289,962.11$) of this estimated economic burden, respectively
Conclusion: The economic burden of AML in Iran is very remarkable and due to the increasing prevalence of this disease, it is expected to increase gradually. Having insights into the costs associated with the disease provide an excellent opportunity for health policymakers and managers to effectively improve resource allocation.
|
| first_indexed | 2024-04-11T01:28:58Z |
| format | Article |
| id | doaj.art-17d3213a877e43f3a1575264064b9145 |
| institution | Directory Open Access Journal |
| issn | 2251-6085 2251-6093 |
| language | English |
| last_indexed | 2024-04-11T01:28:58Z |
| publishDate | 2022-11-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Iranian Journal of Public Health |
| spelling | doaj.art-17d3213a877e43f3a1575264064b91452023-01-03T10:03:32ZengTehran University of Medical SciencesIranian Journal of Public Health2251-60852251-60932022-11-01511110.18502/ijph.v51i11.11178The Economic Burden of Acute Myeloid Leukemia in IranVahid Alipour0Soroush Rad1Shahin Nargesi2Fateme Mezginejad3Reza Jahangiri4Zeinab Dolatshahi5Seyed Asadollah Mousavi6Zahra Moshkani7Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, IranHematology, Oncology, and Hematopoietic Stem Cell Transportation Research Center, Tehran University of Medical Sciences, Teh-ran, IranDepartment of Health Management and Economics, Faculty of Health, Ilam University of Medical Sciences, Ilam, IranCellular and Molecular Research Center, Birjand Iran University of Medical Science, Birjan, IranDepartment of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, IranDepartment of Health Policy, School of Health Management and Information Sciences, Iran University of Medical Sciences, Teh-ran, IranHematology, Oncology, and Hematopoietic Stem Cell Transportation Research Center, Tehran University of Medical Sciences, Teh-ran, IranHealth Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran Background: Cancer imposes a significant economic burden on the health system and society. Acute myeloid leukemia (AML) is the third deadliest leukemia and is one of the leading health problems worldwide. The present study aimed to estimate the economic burden of AML in Iran for 2020. Methods: In this study, we estimated a prevalence-based on the cost-of-illness of the AML in Iran. A societal perspective was considered, in which the direct costs and productivity losses with the adoption of the human capital approach in the AML cases were estimated for 2020. Moreover, in the present study, several resources including national cancer registry reports, hospital records, occupational data, and interviews with experts were cited. Results: Approximately 98% of patients with AML received induction therapy. The AML economic burden was $33,243,107.39. Indirect costs accounted for 60% (21,593,764.4$) of this amount, and direct medical costs and direct non-medical costs make up for 19% (6,359,380.88$) and 16% (5,289,962.11$) of this estimated economic burden, respectively Conclusion: The economic burden of AML in Iran is very remarkable and due to the increasing prevalence of this disease, it is expected to increase gradually. Having insights into the costs associated with the disease provide an excellent opportunity for health policymakers and managers to effectively improve resource allocation. https://ijph.tums.ac.ir/index.php/ijph/article/view/24990Acute myeloid leukemiaConsolidation therapyIranEconomic burden |
| spellingShingle | Vahid Alipour Soroush Rad Shahin Nargesi Fateme Mezginejad Reza Jahangiri Zeinab Dolatshahi Seyed Asadollah Mousavi Zahra Moshkani The Economic Burden of Acute Myeloid Leukemia in Iran Iranian Journal of Public Health Acute myeloid leukemia Consolidation therapy Iran Economic burden |
| title | The Economic Burden of Acute Myeloid Leukemia in Iran |
| title_full | The Economic Burden of Acute Myeloid Leukemia in Iran |
| title_fullStr | The Economic Burden of Acute Myeloid Leukemia in Iran |
| title_full_unstemmed | The Economic Burden of Acute Myeloid Leukemia in Iran |
| title_short | The Economic Burden of Acute Myeloid Leukemia in Iran |
| title_sort | economic burden of acute myeloid leukemia in iran |
| topic | Acute myeloid leukemia Consolidation therapy Iran Economic burden |
| url | https://ijph.tums.ac.ir/index.php/ijph/article/view/24990 |
| work_keys_str_mv | AT vahidalipour theeconomicburdenofacutemyeloidleukemiainiran AT soroushrad theeconomicburdenofacutemyeloidleukemiainiran AT shahinnargesi theeconomicburdenofacutemyeloidleukemiainiran AT fatememezginejad theeconomicburdenofacutemyeloidleukemiainiran AT rezajahangiri theeconomicburdenofacutemyeloidleukemiainiran AT zeinabdolatshahi theeconomicburdenofacutemyeloidleukemiainiran AT seyedasadollahmousavi theeconomicburdenofacutemyeloidleukemiainiran AT zahramoshkani theeconomicburdenofacutemyeloidleukemiainiran AT vahidalipour economicburdenofacutemyeloidleukemiainiran AT soroushrad economicburdenofacutemyeloidleukemiainiran AT shahinnargesi economicburdenofacutemyeloidleukemiainiran AT fatememezginejad economicburdenofacutemyeloidleukemiainiran AT rezajahangiri economicburdenofacutemyeloidleukemiainiran AT zeinabdolatshahi economicburdenofacutemyeloidleukemiainiran AT seyedasadollahmousavi economicburdenofacutemyeloidleukemiainiran AT zahramoshkani economicburdenofacutemyeloidleukemiainiran |